

#5
BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mary Faris et al.

Examiner:

Serial No.: 09/809,638

Group Art Unit:


Filed: March 14, 2001

Docket: G&C 129.35-US-01

Title: 125P5C8: A TISSUE SPECIFIC PROTEIN HIGHLY EXPRESSED IN VARIOUS CANCERS

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 30, 2001.

By: 
Name: Karen S. Canady

STATEMENT REGARDING SEQUENCE LISTING
UNDER 37 CFR §§ 1.821-1.825

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


In accordance with 37 CFR § 1.821(f), Applicants hereby state that the paper and computer readable copies of the Sequence Listing submitted herewith in connection with above-identified patent application are the same. The Sequence Listing submitted herewith does not include new matter or matter which goes beyond the application as originally filed.

Respectfully submitted,

GATES & COOPER LLP
Attorneys for Applicant(s)

Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797

Date: 7/30/01

By: 
Name: Karen S. Canady
Reg. No.: 39,927

G&C 129.35-US-01